Emerging pharmaceutical therapies for osteoarthritis

Latourte, Augustin; Kloppenburg, Margreet; Richette, Pascal

doi:10.1038/s41584-020-00518-6

Cited by 280 publications

(222 citation statements)

References 216 publications

Supporting

Mentioning

219

Contrasting

Unclassified

Order By: Relevance

“…Thus, the guidelines from the United States Food and Drug Administration (FDA) and the European Medicines Agency (EMA) point out that the effective diseasemodifying osteoarthritis drugs (DMOADs) should be developed (Reginster et al, 2015;Oo et al, 2018). A DMOAD is expected a drug that modifies the underlying OA pathophysiology, thereby inhibiting structural damage to prevent or reduce long-term disability and offer potential symptomatic relief (Latourte et al, 2020). Currently, there are no US FDA-or EMAapproved DMOADs.…”

Section: Infliximabmentioning

confidence: 99%

“…With the population aging and obesity, the incidence of OA is increasing as a leading cause of disability worldwide (Peat and Thomas, 2020). To date, no effective drug is able to inhibit the structural damage or reduce long-term disability, or relieve pain with an acceptable benefit-to-risk profile in OA (Latourte et al, 2020). For these reasons, the OARSI led an effort to submit a White Paper to the FDA in support of the designation of OA as a serious disease in 2016.…”

Section: Expert Opinionmentioning

confidence: 99%

See 1 more Smart Citation

New Trends in Pharmacological Treatments for Osteoarthritis

et al. 2021

View full text Add to dashboard Cite

Osteoarthritis (OA) is the leading cause of function loss and disability among the elderly, with significant burden on the individual and society. It is a severe disease for its high disability rates, morbidity, costs, and increased mortality. Multifactorial etiologies contribute to the occurrence and development of OA. The heterogeneous condition poses a challenge for the development of effective treatment for OA; however, emerging treatments are promising to bring benefits for OA management in the future. This narrative review will discuss recent developments of agents for the treatment of OA, including potential disease-modifying osteoarthritis drugs (DMOADs) and novel therapeutics for pain relief. This review will focus more on drugs that have been in clinical trials, as well as attractive drugs with potential applications in preclinical research. In the past few years, it has been realized that a complex interaction of multifactorial mechanisms is involved in the pathophysiology of OA. The authors believe there is no miracle therapeutic strategy fitting for all patients. OA phenotyping would be helpful for therapy selection. A variety of potential therapeutics targeting inflammation mechanisms, cellular senescence, cartilage metabolism, subchondral bone remodeling, and the peripheral nociceptive pathways are expected to reshape the landscape of OA treatment over the next few years. Precise randomized controlled trials (RCTs) are expected to identify the safety and efficacy of novel therapies targeting specific mechanisms in OA patients with specific phenotypes.

show abstract

Section: Infliximabmentioning

confidence: 99%

Section: Expert Opinionmentioning

confidence: 99%

New Trends in Pharmacological Treatments for Osteoarthritis

et al. 2021

View full text Add to dashboard Cite

show abstract

“…Most trials conducted to date have produced inconclusive results [47]. This means that the novel pharmacological agents, disease-modifying OA drugs (DMOADs) [48][49][50] and biological interventions that are currently being tested must have an impact on joint structure (i.e., articular cartilage) and the symptoms of pain, even if the trials include surrogate endpoints and post-marketing confirmatory data under the accelerated drug approval regulations set forth by the Food and Drug Administration (FDA) [51].…”

Section: Existing Recommended Treatments For Oamentioning

confidence: 99%

Neuroscience and Neuroimmunology Solutions for Osteoarthritis Pain: Biological Drugs, Growth Factors, Peptides and Monoclonal Antibodies Targeting Peripheral Nerves

Mobasheri

2021

NeuroSci

View full text Add to dashboard Cite

Neuroscience is a vast discipline that deals with the anatomy, biochemistry, molecular biology, physiology and pathophysiology of central and peripheral nerves. Advances made through basic, translational, and clinical research in the field of neuroscience have great potential for long-lasting and beneficial impacts on human and animal health. The emerging field of biological therapy is intersecting with the disciplines of neuroscience, orthopaedics and rheumatology, creating new horizons for interdisciplinary and applied research. Biological drugs, growth factors, therapeutic peptides and monoclonal antibodies are being developed and tested for the treatment of painful arthritic and rheumatic diseases. This concise communication focuses on the solutions provided by the fields of neuroscience and neuroimmunology for real-world clinical problems in the field of orthopaedics and rheumatology, focusing on synovial joint pain and the emerging biological treatments that specifically target pathways implicated in osteoarthritis pain in peripheral nerves.

show abstract

“…Most trials conducted to date producing inconclusive results [26]. This means that the novel pharmacological agents, disease-modifying OA drugs (DMOADs) [27][28][29] and biological interventions that are currently being tested need to impact on joint structure (i.e. articular cartilage) and the symptoms of pain, even if they include surrogate endpoint and post-marketing confirmatory data under the accelerated drug approval regulations set forth by the Food and Drug Administration (FDA) [30].…”

Section: Existing Recommended Treatments For Oamentioning

confidence: 99%

Neuroscience and Neuroimmunology Solutions for Osteoarthritis Pain: Biological Drugs, Growth Factors, Peptides and Monoclonal Antibodies Targeting Peripheral Nerves

Mobasheri¹

2020

Preprint

View full text Add to dashboard Cite

Neuroscience is a vast discipline that deals with the anatomy, biochemistry, molecular biology, physiology and pathophysiology of central and peripheral nerves. Advances made through basic, translational, and clinical research in the field of neuroscience have great potential for long-lasting and beneficial impacts on human health. The emerging field of biological therapy is intersecting with the disciplines of neuroscience and rheumatology, creating new horizons for interdisciplinary and applied research. Biological drugs, growth factors, neuropeptides and monoclonal antibodies are being developed and tested for the treatment of painful arthritic and rheumatic diseases. This concise communication focuses on the solutions provided by the fields of neuroscience and neuroimmunology for real-world clinical problems in the field of rheumatology, focusing on synovial joint pain and the emerging biological treatments that specifically target pathways implicated in osteoarthritis pain in peripheral nerves.

show abstract

Emerging pharmaceutical therapies for osteoarthritis

Cited by 280 publications

References 216 publications

New Trends in Pharmacological Treatments for Osteoarthritis

New Trends in Pharmacological Treatments for Osteoarthritis

Neuroscience and Neuroimmunology Solutions for Osteoarthritis Pain: Biological Drugs, Growth Factors, Peptides and Monoclonal Antibodies Targeting Peripheral Nerves

Neuroscience and Neuroimmunology Solutions for Osteoarthritis Pain: Biological Drugs, Growth Factors, Peptides and Monoclonal Antibodies Targeting Peripheral Nerves

Contact Info

Product

Resources

About